Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Titel:
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Auteur:
Mutlu, Levent McNamara, Blair Bellone, Stefania Manavella, Diego D. Demirkiran, Cem Greenman, Michelle Verzosa, Miguel Skyler Z. Buza, Natalia Hui, Pei Hartwich, Tobias Max Philipp Harold, Justin Yang-Hartwich, Yang Zipponi, Margherita Altwerger, Gary Ratner, Elena Huang, Gloria S. Clark, Mitchell Andikyan, Vaagn Azodi, Masoud Schwartz, Peter E. Santin, Alessandro D.